AbbVie to Showcase Breadth of Oncology Portfolio and Pipeline at the 2021 ASCO and EHA Annual Congresses

NORTH CHICAGO, Ill., May 19, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) will present results from 43 abstracts across 12 types of cancer during the upcoming virtual American Society of Clinical Oncology (ASCO) Annual Meeting (June 4-8) and the virtual European Hematology Association (EHA) congress (June 9-17). “We are advancing discovery and innovation Read more…

Avapritinib Provided Greater Benefit Than Other Tyrosine Kinase Inhibitors for Mutated Gastrointestinal Stromal Tumors

Data from a new study by researchers at Fox Chase Cancer show that avapritinib, a platelet-derived growth factor receptor A (PDGFRA) inhibitor, has a “clinically meaningful benefit” for the treatment of gastrointestinal stromal tumors (GIST) with PDGFRA D842V mutations. According to lead author Margaret von Mehren, MD, chief of the Division of Sarcoma Medical Read more…

With 80,000 Participants, the Largest Study of Its Kind Is the First to Evaluate the Benefits of Screening for a Precursor to the Blood Cancer Multiple Myeloma

The IMF-funded iStopMM study (Iceland Screens, Treats, or Prevents Multiple Myeloma) is the largest study of its kind, with a record-setting 80,759 participants. A cancer of the bone marrow plasma cells, multiple myeloma is always preceded by a condition called MGUS, in which an abnormal protein appears in the blood. Read more…

The Center for International Blood and Marrow Transplant Research (CIBMTR) Launches Study of COVID-19 Vaccine Immunogenicity in Patients With Hematological Malignancies Who Have Received Cellular Therapy

The CIBMTR® (Center for International Blood and Marrow Transplant Research®) announces the launch of a large observational study, done in collaboration with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to understand the safety, efficacy, and durability of responses to COVID-19 vaccines in patients with hematological malignancies and non-malignant Read more…

BeiGene Announces Positive Topline Results from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Phase 3 RATIONALE 309 trial of its anti-PD-1 antibody tislelizumab combined with chemotherapy versus placebo combined with chemotherapy as a first-line treatment for patients with recurrent or metastatic nasopharyngeal Read more…